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Abstract
Human hepatocyte transplantation has been actively perused as an alternative to liver replacement for acute liver failure
and liver-based metabolic defects. Current challenges in this field include a limited cell source, reduced cell viability
following cryopreservation and poor engraftment of cells into the recipient liver with consequent limited life span. As a
result, alternative stem cell sources such as pluripotent stem cells, fibroblasts, hepatic progenitor cells, amniotic epithelial
cells and mesenchymal stem/stromal cells (MSCs) can be used to generate induced hepatocyte like cells (HLC) with each
technique exhibiting advantages and disadvantages. HLCs may have comparable function to primary human hepatocytes
and could offer patient-specific treatment. However, long-term functionality of transplanted HLCs and the potential
oncogenic risks of using stem cells have yet to be established. The immunomodulatory effects of MSCs are promising,
and multiple clinical trials are investigating their effect in cirrhosis and acute liver failure. Here, we review the current
status of hepatocyte transplantation, alternative cell sources to primary human hepatocytes and their potential in liver
regeneration. We also describe recent clinical trials using hepatocytes derived from stem cells and their role in improving
the phenotype of several liver diseases.
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Introduction
The liver is responsible for a diverse range of functions within
the body ranging from xenobiotic metabolism to plasma pro-
tein synthesis [1]. However, the liver can become susceptible
to acute failure (ALF) due to viral infection or drug effect
amongst other aetiologies [2]. Liver-based metabolic disor-
ders that are caused by single-gene defects can result in a lack
of specific liver-based enzyme function which may result in
damage to other organs most often irreversible neurodisability
[3]. Orthotopic liver transplantation (OLT) is currently the
only viable treatment for severe ALF and certain liver-based
metabolic disorders [2, 4, 5]. Liver replacement is not futuris-
tic for liver-based metabolic defects where gene therapy
would be ideal. Notably, a shortage in healthy donor livers
has led to research into alternative treatment options [6].
Hepatocyte transplantation (HT), where liver cells may pro-
vide a potential alternative to OLT or act as a bridge until a
suitable organ becomes available, has been demonstrated,
with over 100 cases published worldwide showing the safety
and preliminary efficacy of the technique [7, 8].
This review will focus on the current status of HT, alternate
cell sources to primary human hepatocytes and alternate
methods of liver regeneration which can be used either inde-
pendently or in combination with HT.
The current status of hepatocyte
transplantation
HT is a less invasive alternative to OLT. Hepatocytes are iso-
lated from donor livers that have been rejected for organ trans-
plantation in view of prolonged warm or cold ischaemia times,
mild steatosis or aberrant anatomy. Hepatocytes isolated from
one donor liver can yield a high quantity of cells and be used
to treat multiple patients [9, 10]. The ability to cryopreserve
these cells is one of the major advantages of HT, potentially
providing an off-the-shelf treatment and enabling cells of all
blood groups to be immediately available for emergency
cases, which is particularly important for patients with ALF.
Several routes of infusion for cell transplantation have been
described including intraportal, intrasplenic and intraperitone-
al. Depending on the age of the patient, infusion of hepato-
cytes into the portal vein can be undertaken via the umbilical
vein under fluoroscopy to avoid a patent ductus venous. In
older children, radiological or surgical catheters are required
using radiological guidance [11–13].
Hepatocyte transplantation can be used to treat patients
with liver-based metabolic diseases and ALF [7, 14, 15].
Metabolic liver diseases treated using HT include Crigler-
Najjar syndrome type 1 (CN-1), urea cycle defects and factor
VII (fVII) deficiency [16]. Crigler-Najjar syndrome has an
incidence of 1 in 1,000,000 births in the UK, and although
the primary long-term treatment is liver transplantation, the
lack of an appropriately sized, blood matched donor organ
can lead to irreversible neurological disability. There are re-
ports of 8 patients that have received between 1.4 and 7.5
billion hepatocytes, which showed up to a 50% reduction in
bilirubin and UGT activity and a decrease in the need for
phototherapy. The majority of these patients went onto receive
an OLT within a year as the effects of HT were not long
lasting, with one patient avoiding OLT for 4 years [16–21].
Several urea cycle defects have also been shown to benefit
from hepatocyte infusions. This includes ornithine
transcarbamylase deficiency (OTC), which is an X-linked ge-
netic condition affecting males that causes hyperammonemia
and can also lead to neurological implications including devel-
opmental delay and learning disabilities. HT led to decreased
ammonia levels and increased urea production in six of these
patients, with four receiving an OLTwithin 7 months and two
reported mortalities [14, 22–25]. Other metabolic liver diseases
shown to improve following HT include familial hypercholes-
terolemia where there was up to a 20% decrease in LDL in
three patients, fVII deficiency where there was a 70% decrease
in the need for recombinant fVII for 6 months and ASL defi-
ciency where the was a decrease in ammonia production and
increased psychomotor abilities [26–28]. Nevertheless, the
long-term benefits of HT for the treatment of patients with
liver-based metabolic disease have yet to be shown.
HT can also be used in patients with ALF. Although liver
transplantation is the primary treatment, paediatric patients
may die whilst waiting for an appropriately size and blood-
matched liver, with no other treatment being shown to im-
prove survival [29]. Furthermore, existing listing criteria are
not robust in terms of accurately predicting death and survival;
hence, some patients receive a liver transplantation, even if
their liver may spontaneously recover, leading to unnecessary
surgeries with life-long immunosuppression. Thirty-seven pa-
tients with acute liver failure have received human hepato-
cytes for both drug induced, viral and idiopathic ALF. Ten
of these patients underwent intraportal hepatocyte infusions,
with two making a full recovery without the need for OLTand
three were successfully bridged to transplantation [15, 30–33].
However, there is a high risk associated with placing
intrahepatic invasive catheters in coagulopathic patients. As
an alternative, it is possible to encapsulate hepatocytes in al-
ginate microbeads made from purified alginate using an
encapsulator [34]. The semi-permeable membrane within the
microbeads allows exchange of metabolites, maintaining syn-
thetic detoxification function, whilst also protecting against
immunocompetent cells by preventing the entry of antibodies
[35, 36]. Hepatocyte-containing microbeads are transplanted
into the intraperitoneal cavity. The transplanted hepatocytes
can assist the necessary liver functions, allowing the liver to
recover. After full recovery, usually 1 month, the microbeads
can be removed using a laparoscopic peritoneal lavage.
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Despite extensive clinical data, long-term clinical out-
comes of HT have yet to be established with any type of
liver-based metabolic disease or ALF. There are still many
limitations to the technique, and current research aims to over-
come this. Firstly, the cryopreservation process requires fur-
ther optimisation with the current protocol resulting in low
viability and function of hepatocytes post-thawing.
Furthermore, transplanted donor hepatocytes undergo im-
mune rejection with up to 70% of engrafted cells cleared with-
in the first 24 h post-transplantation [37]. Upon transplanta-
tion, donor hepatocytes are recognised and activate the instant
blood-mediated inflammatory reaction, during which both the
complement and coagulation pathways are activated. Innate
immune cells such as Kupffer cells, natural killer cells and
monocytes rapidly clear transplanted donor hepatocytes [38,
39]. Amajor limitation of HT is the lack of good quality donor
organs from which to isolate cells from. Neonatal livers have
been investigated as a potential cell source as they are infre-
quently used for OLT due to the high incidence of hepatic
artery thrombosis [40]. However, they may be an ideal cell
source for HT, with one study demonstrating their mature
function of cytochrome P450 and ureagenesis enzymes, with
increased attachment efficiency and viability compared to he-
patocytes isolated from adult donor livers [41, 42]. Currently,
the number of neonatal donations is not sufficient to maintain
an active clinical HT programme [41, 43]. As a result, there is
a requirement to investigate alternative cell sources to resolve
the shortage of healthy donor organs and avoid recipient im-
mune rejection (Fig. 1 and Table 1).
Alternative cell sources for hepatocyte
transplantation
Induced pluripotent stem cells generated
from somatic cells
Induced pluripotent stem cells (iPSCs) that can be differenti-
ated into hepatocyte-like cells (HLCs) are being widely ex-
plored as an alternative to primary human hepatocytes. These
cells offer an excellent alternative source of hepatocytes and
are advantageous over primary human hepatocytes because of
their unlimited cell source and their ability to avoid the im-
mune system [44]. Methods to produce iPSC-derived HLCs
are well established, with most protocols using a three-
dimensional matrix such as Matrigel® to establish the gener-
ation of hepatocytes. However 2Dmatrices including collagen
have also shown successful iPSC to HLC differentiation [45,
46]. An effective protocol for generating HLCs has been
established via the use of specific growth factors such as
activin A and bone morphogenetic protein 4 (BMP4), which
are crucial for initiating the first step of hepatic maturation.
Hepatocyte-growth factor (HGF) and oncostatin stimulate
hepatoblast formation and hepatocyte-like differentiation, re-
spectively. Si-Tayeb et al. showed that iPSC-derived HLCs
displayed hepatic functionality, including glycogen accumu-
lation, lipoprotein uptake and urea synthesis [47]. iPSCs are
advantageous over primary human hepatocytes as generation
from somatic cells of an individual will prevent activation of
the recipient’s immune response, avoiding the use of immu-
nosuppressive drugs [38, 45, 48, 49]. iPSCs can proliferate
indefinitely, forming a limitless pool of HLCs allowing pa-
tients to receive multiple infusions if necessary [48, 50].
iPSC-derived HLCs can also be used as a model for several
metabolic liver diseases including familial hypercholesterol-
emia, α1-antitrypsin deficiency and glycogen storage disease
type 1a. By generating cells with similar phenotypes to those
caused by inherited diseases, it is possible to study the mech-
anisms of dysregulated cellular functions and identify ways to
treat or reverse the condition [51]. Currently, the functional
ability of HLCs is not comparable to human primary hepato-
cytes. Yu et al. showed that HLCs co-express alpha-fetopro-
tein and albumin, suggesting that they are not fully mature.
Levels of albumin synthesis, urea production, cytochrome
p450 activity and mitochondrial function are also significantly
lower than human primary hepatocytes [50]. Furthermore,
there are genetic variations in donor cells that effect the dif-
ferentiation propensity of iPSCs which has been attributed to
genetic variation of the donor, cell culture conditions and
iPSC generation protocols [52, 53]. Following the develop-
ment of new hepatic differentiation protocols, Kajiwara et al.
compared 28 iPSC lines derived from different somatic cells
and showed that it was the origin of the donor cells that deter-
mined the variation in hepatic differentiation and not the der-
ivation method [53].With albumin used as a marker to assess
functionality, HLCs derived from human dermal fibroblast-
iPSCs and peripheral blood cell-iPSCs showed minimal vari-
ation in hepatic differentiation from the same donor; however,
inter-donor hepatic variation was more prominent. This cre-
ates a complication when using iPSCs for therapeutic use as
non-identical cell lines cannot guarantee the same quality of
HLC production [48, 53].
In addition, the tumorigenic potential of these cells due to
the presence of oncogenes such as c-Myc may raise a safety
concern regarding the clinical application of these cells. Chen
et al. reported no formation of teratomas or tumours in Gunn
rats transplanted with HLCs, suggesting a loss of pluripotent
characteristics within these cells [54]. Although HLCs repre-
sent an ideal cell source for HTwith no risk of rejection, work
is still ongoing to advance their functional capacity and fully
validate the safety and efficacy of using these stem cells.
Fibroblasts
Human fibroblasts offer another potential source of HLCs for
HT. Fibroblasts are connective tissue cells found in all areas of
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the human body [55]. Huang et al. established the first
reprogramming of human fibroblasts to hepatocytes using
both foetal and adult connective tissue cells. Using lentivi-
ruses as a vector for expressing transcription factors, hepato-
cyte nuclear factor 1 homeobox alpha (HNF1A), HNF4A and
FOXA3, successful fibroblast to HLC transformation has
been achieved, with HNF1A being crucial for the human
fibroblast reprogramming [56]. Simeonov et al. also achieved
fibroblast transformation using exogenous HNF1Amessenger
RNA (mRNA) [57]. Within the same year, Du et al. derived
HLCs from human fibroblasts, with the generated hepatocytes
possessing phase I/II/III drugmetabolic activity comparable to
primary human hepatocytes [58]. Fibroblast-derived HLC
production requires only a single transformation step and they
Fig. 1 Potential alternative cell sources (induced pluripotent stem cells,
fibroblasts, mesenchymal stem/stromal cells and hepatic progenitor cells)
which can be used to generate hepatocytes. Gene transfer is used to
convert somatic cells to iPSCs and fibroblasts to HLCs. All other trans-
formations occur under culture conditions. HLC induced hepatocyte,
iPSC induced pluripotent stem cells, MSC mesenchymal stem cells,
HPC hepatic progenitor cells, hAEC human amniotic epithelial cells,
BMP bone morphogenetic protein, OSM oncostatin M, HGF hepatic
growth factor, HNF1A hepatocyte nuclear factor 1 homeobox alpha,
HNF4A hepatocyte nuclear factor 4 alpha, FGF fibroblast growth factor,
EGF epidermal growth factor, Dex dexamethasone, FBS foetal bovine
serum
Table 1 Summary of selected clinical trials globally, researching the therapeutic benefits of alternative cell sources in liver disease
Alternative cell sources Advantages Disadvantages
Induced pluripotent stem
cells (iPSC)
• Patient-specific cell generation
• Reduced immune response
• Disease modelling
• Limitless pool of cells
• Inadequate long-term functionality
• Potential tumour formation
Fibroblasts • Patient-specific cell generation
• Reduced immune response
• Disease modelling
• Proliferation arrest
• Residual epigenetic memory
• Resistant to transformation
Mesenchymal stem/stromal
cells (MSC)
• Patient-specific cell generation
• Immune modulation
• Easily accessible from several tissues of the body
• Could potentially lose functionality
Hepatic progenitor
cells (HPC)
• Naturally differentiate into new hepatocytes
• Can be used to generate a number of new hepatocytes
• Considered to be involved in hepatocyte regeneration
• Could play no role in liver regeneration
• May be involved in the progression of liver fibrosis
• Acquired from donor livers so may cause immune rejection
• Immunosuppressive drugs would be required
Amniotic epithelial
cells (hAEC)
• Reduced risk of tumour formation
• Easily accessible
• Reduced ethical implications
• Reduced immune reaction
• Gene expression similar to foetal cells rather
than adult hepatocytes
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can be patient-specific, reducing the chances of immune re-
jection and avoiding the use of immunosuppressive drugs [38,
49, 56]. Despite these advantageous, fibroblast-derived HLCs
have therapeutic limitations. They have a limited reproduc-
tive capability and cannot be used for repeat infusions in a
single patient. Furthermore, human fibroblasts are resistant
to hepatic transdifferentiation, thereby creating an addition-
al barrier when generating HLCs [56]. Hepatocytes gener-
ated from reprogrammed fibroblasts may still retain epige-
netic memory from the fibroblast cell of origin. This creates
limitations when choosing fibroblasts for hepatic transfor-
mation, as cells with significant epigenetic differences to
hepatocytes may be further resistant to reprogramming
and reduced functionality [59].
Hepatic differentiation of amniotic epithelial cells
It is also possible to generate hepatocytes from amniotic epi-
thelial cells. These cells have stem cell markers such as OCT-
4, Nanog, SOX-2 and Rex-1, and as they do not have telome-
rase reverse transcriptase, they show a stable phenotype with-
out the risk of tumorigenic potential [60]. Such cells have
minimal ethical implications, and there is no shortage of pla-
cental tissue from which to isolate the cells. Following culture
in Matrigel® or liver-derived ECM, these cells had albumin
and CYP3A4, 3A7, 2B6 and 2D6 mRNA levels which in-
creased over time with a peak at day 21 [61]. Following trans-
plantation into the SCID mouse, genes were expressed for
human cytochrome p450 genes, metabolic enzymes and
hepatocyte-enriched transcription factors and plasma proteins
6 months post-transplantation. It has now been suggested that
hepatic differentiation of amniotic epithelial cells (hAECs)
represent a promising non-controversial, unlimited source of
cells for liver-based metabolic diseases.
The regenerative capacity of resident liver cell hepatic
progenitor cells
Hepatic progenitor cells (HPCs), also known as oval cells, are
believed to differentiate into mature hepatocytes or
cholangiocytes, upon liver damage and help in tissue restora-
tion. HGF and EGF are critical in inducing the transformation of
HPC into hepatocytes. HGF activates the MET receptor, which
further upregulates the expressions of AKT and STAT3 driving
hepatic transformation. A lack of MET receptors completely
attenuates HPC to hepatocyte differentiation even in the pres-
ence of EGFR. However, EGFR-null HPCs were still able to
sufficiently transform into hepatocytes with MET alone [62].
Zhang et al. established in vitro generation of HLCs from
human foetal HPCs, under the influence of oncostatin M
(OSM), DEX andHGF. These newly differentiated hepatocytes
have functional glycogen storage, albumin secretion and cyto-
chrome p450 activity with Khuu et al., suggesting that in vitro
differentiated adult hepatic stem cells are also capable of urea
production and ammonium chloride metabolism [63, 64].
Unlike some other HLCs, hepatocytes formed from liver-
derived progenitor cells have reached clinical application.
Sokal et al. transplanted HPCs in a 3-year-old female patient
suffering with OTC deficiency. Previous transplantation of
cryopreserved hepatocytes failed to improve the patient’s
symptoms. Fourteen weeks post-infusion, biopsies showed
3% presence of donor cells and the patient showed some func-
tional improvement with a reduction in disease-related anorex-
ia. Unfortunately, 6 months post-infusion, the child underwent
OLTand later died. These results suggest that HPCs could play
a role in treatment of metabolic liver disease; however, longer-
scale clinical trials are required to assess their full potential [65].
Human bile duct cells
In addition to HPCs, mature hepatocytes can be derived from a
number of other resident cell types within the liver. Huch et al.
established a protocol differentiating primary human bile duct
cells (EpCAM+) into genetically stable functional HLCs in both
in vitro and in vivo transplantations. Organoids were formed
using ductal cells, and usingmedium consisting of BMP7, EGF
and HGF, successful hepatic differentiation was achieved.
Newly formed HLCs demonstrated albumin production,
CYP3A3/4/5 activity and bile acid secretion. Furthermore,
organoids successfully engrafted into Balb/c nude mice with
induced liver damage, sustaining albumin and α-1-antitrypsin
levels for up to 120 days in two out of five recipient mice.
Debate remains over the genetic stability of fibroblasts and
iPSCs as cell sources for HLCs. The expandable nature and
genetic stability of HLCs derived from human bile ductal cells
makes them a desirable alternate cell source [66].
Chemically induced liver progenitors
Recently, it has been shown that mature hepatocytes convert to
HLCs during chronic liver injury [67]. Katsuda et al. showed
that a cocktail of small molecules Y-27632, A-83-01 and
CHIR99021 could contribute to the induction and maintenance
of bipotent chemically induced liver progenitor cells (CLiPs).
These cells could either be differentiated into mature hepato-
cytes or biliary epithelial cells. Rat CLiPs were capable of
repopulating immunodeficient mice with chronic liver injury.
Albumin levels were used to assess liver functionality, which
showed a consistent increase up until 8 weeks post-transplanta-
tion. Immunohistochemistry showed that up to 75–90% of the
mouse liver had been replaced by rat hepatocytes, demonstrating
a selective proliferative advantage for the healthy donor cells.
Mouse ductal structures also showed CLiPs-derived cell re-
placement, displaying the biopotency of the lineage. If similar
protocols could be established using human hepatocytes, this
offers an additional source for HLCs for use in HT.
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Furthermore, the bipotent properties of CLiPs suggest that they
could be used to tackle diseases related to the biliary tree as well
as the liver [68].
The role of mesenchymal stem/stromal cells
in liver-based regenerative medicine
Mesenchymal stem/stromal cells (MSCs) have been investi-
gated as another cell source for hepatocyte differentiation but
with limited and controversial results. More promising is their
immunogenic effect, and now,MSCs are being investigated as
an immunomodulatory therapy to treat liver a number of dif-
ferent liver diseases.
MSCs can be isolated from various tissues, such as bone
marrow, adipose tissue and the umbilical cord. BMP and fi-
broblast growth factor (FGF) induction lead to the differenti-
ation of MSCs to the hepatic lineage, with dexamethasone
(DEX) and IL-16 inducing hepatic maturation. Single-step
procedures are also commonly used with HGF and epidermal
growth factor (EGF). Transformed cells generated from this
procedure usually exhibit functional hepatic properties 2–
3 weeks post-culturing but do lose functional capabilities
when cultured for prolonged periods [69]. Furthermore, it is
still debated whether MSC-derived hepatocytes are able to
efficiently re-populate a host liver to provide adequate func-
tion and clinical application is still in its infancy [70]. Perhaps
of greater potential is the immunomodulatory effect of MSCs.
MSCs play a key role in immune modulation due to their lack
of MHC-I/MHC-II receptors and are unlikely to trigger a T
cell response. Furthermore, MSCs are considered to reduce T
cell proliferation and cytotoxicity, as well as improving liver
injury and enhancing liver regeneration [71, 72]. This immune
evasion capability has resulted in MSCs adopting the title of
Bimmunoprivileged^ or Bimmunotolerant^ cells [73]. Thus,
MSCs could be used in conjunction with hepatocytes dur-
ing HT to increase engraftment and reduce the immune
response. Hwang et al. showed that intrasplenic transplan-
tation of MSC-derived HLCs restored liver functionality in
rat models with thioacetamide-induced liver cirrhosis.
Naïve implanted MSCs firstly transdifferentiated into he-
patic oval cells and later into HLCs. The presence of newly
formed HLCs reduced inflammation, reversed fibrosis and
repaired damaged hepatocytes. The exact mechanism by
which MSCs induce hepatic recovery is unclear, but the
authors suggest that activation of humoural factors could
contribute to liver regeneration [74].
Mechanisms of MSCs in liver regeneration
Recently, it has been suggested that MSCs modulate liver fail-
ure by several mechanisms including differentiation of MSCs
to replace damaged cells, secretion of soluble factors by MSCs
to promote liver repair, MSC-mediated transfer of mitochondria
by tunnelling nanotubules and by MSC-mediated transfer of
proteins, RNA, hormones and chemicals by extracellular vesi-
cles such as exosomes or microvesicles [75].
MSC conditioned medium (MSC-CM) can play an impor-
tant role in attenuating liver disease with awide range of soluble
factors thought to be present withinMSC-CM [76]. Interleukin-
6 secreted by MSCs reduces apoptosis in liver injury [77].
Furthermore, MSC secreted TGF-β and nerve growth factor
resulted in apoptosis of hepatic stellate cells, a hallmark of liver
fibrosis [78, 79]. Huang et al. showed that mice with fulminant
hepatic failure (FHF) and chronic liver failure treated with
MSCs or MSC-CM displayed reduced liver pathology. Only
MSC treatment of FHF mice showed great reduction in pro-
inflammatory T helper-1/17 cells and upregulation of T regula-
tory cells. This indicates that direct presence of MSCs is re-
quired to induce complete immunomodulatory effects [].
In addition to soluble factors present inMSC-CM, recently,
exosomes have been identified as an important component
that may promote hepatic regeneration. Tan et al. (2014)
showed that CCL4-induced liver injury reduced AST and
ALT levels and decreased the number of necrotic cells in mice
that were treated with MSC-derived exosomes. Furthermore,
proliferation of hepatocytes was greater, which was associated
with increased expression of proliferating cell nuclear antigen
[80]. The authors suggest that MSC-derived exosomes may
have a therapeutic potential in toxic liver injury. It has also
been suggested that tunnelling nanotubules can form between
cells that act as a transport network, allowing the transport of
mitochondria and lysosomal vesicles [81]. Currently, the
transfer of mitochondria through tunnelling nanotubules from
umbilical cord-derived MSCs to hepatocytes is being investi-
gated as a mechanism for their increased survival and function
and may play a role in liver regeneration [82].
MSCs represent an ideal cell source for liver regeneration-
based medicine due to their easily accessible source, their
immunomodulatory properties and their potential of
transdifferentiating into hepatocytes.
Current clinical trials using cell therapy
for liver-based diseases
There are now multiple phase I/II and III clinical trials using
different types of stem cells to improve a number of liver
diseases including cirrhosis, liver failure and liver-based met-
abolic disorders. In liver cirrhosis and end-stage liver disease,
reports have proposed that MSCs can replace hepatocytes in
the injured liver, stimulating liver regeneration (Table 2).
Shi et al. (2012) showed that transfusion of umbilical cord-
MSC (UC-MSC) into 24 patients with acute-on-chronic liver
failure showed marked increase in liver functionality when
compared to the control of 19 patients transfused with saline.
J Mol Med
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Patients were monitored over 48 weeks, with the treatment
group showing an increase in albumin secretion, platelet count
and a reduced end-stage liver disease (MELD) score.
Furthermore, survival rate after 72 weeks was also higher in
the treatment group compared to the control, with 20.8 and
47.4% mortality rate, respectively. The author suggests that
although the mechanism of improved liver function may be
unclear, in vivo differentiation of UC-MSC into hepatocytes
is unlikely due to the short period of hepatic recovery and with
only one treatment patient showing increased alpha-fetoprotein
levels. It is more likely that soluble factors produced by MSCs
may enhance liver revascularization and proliferation [93].
One study has suggested that plasma exchange (PE) helps
promote liver regeneration and recovery, leading to UC-MSC
differentiation into HLCs. A phase I/II clinical trial is now in
progress, transplanting UC-MSCs into patients with liver fail-
ure. Patients received either conventional treatment (anti-viral
drugs) with UC-MSCs and/or PE treatment, and survival rates
were assessed at 48 weeks [96]. For patients with acute-on-
chronic liver failure, Promethera Biosciences have developed
a product known as HepaStem, which are MSCs that have the
potential to differentiate into HLCs. A phase IIa clinical trial is
now in progress, transplanting these cells via IV injection to
establish the safety and biological efficacy of these cells.
Bilirubin, creatinine, INR and albumin values are being
assessed at day 28, 2 months and 1 year post-infusion. In addi-
tion to using stem cells for liver failure, HLCs are now being
used for clinical HT to replace primary hepatocytes in patients
with liver-based metabolic disorders. Bone marrow-derived
MSCs transdifferentiated into hepatocytes have been
transplanted via the portal vein into patients with familial hy-
percholesterolemia. Serum cholesterol/LDL levels were
assessed after 6 months to determine the efficacy of the tech-
nique. Furthermore, HepaStem cells are also being used to treat
patients suffering from urea cycle disorders. Ureagenesis, am-
monia values and amino acid levels are beingmonitored as well
as behaviour, cognitive skills and health-related quality of life
indicators for up to 12 months post-infusion [94].
MSCs are also being used clinically for immunomodulating
therapy in many liver-based applications. One trial is currently
investigating the use of MSCs to promote allograft tolerance
and reduce the toxicity that results from exposure to calcineurin
inhibitors. Paediatric patients receiving a liver transplantation
undergo IV injection of bone marrow-derived MSCs. MSC
toxicity is being monitored as well as graft function measured
by aminotransferase and gamma glutamyl transferase activity,
bilirubin, albumin and INR and the individual need for immu-
nosuppressive medication. In addition, MSCs are being used as
immunomodulators in ABO-incompatible liver transplantation.
The study aims to determine if MSCs are safe and effective at
reducing the primary non-function, acute rejection, ischaemic-
type biliary lesions and morbidity in ABO-incompatible liver
transplantation.
Another promising area could be the use of macrophage
therapy to treat liver disease. Macrophages reduce scar tissue
and stimulate the HPCs to expand and differentiate into mature
hepatocytes. Thomas et al. showed that bone marrow-derived
macrophages (BMM) administered tomice with advanced liver
fibrosis resulted in a degradation of fibrillar collagen and re-
duced fibrogenesis. There was also upregulation of the liver
progenitor cell mitogen tumour necrosis factor-like weak in-
ducer of apoptosis that was associated with an expansion of
the progenitor cell compartment [95]. There are ongoing clini-
cal trials to assess the role macrophage therapy could play in
liver cirrhosis [89]. Significant advances have been made to
translate the use of stem cells to promote liver regeneration
and mature hepatic differentiation into clinical use. Currently,
most trials are in early phase I/II and results demonstrating the
efficacy of these techniques are yet to be published. In the near
future, the full potential of stem cells for liver regeneration in
patients with liver disease may be better established.
Conclusion
HToffers an alternative therapy to OLTwith the aim of treating
liver-based metabolic diseases or ALF. Advances in liver cell
therapy are being researched to overcome the obstacles associ-
ated with HT, particularly the shortage of healthy donor hepa-
tocytes. Although HLCs are promising, no alternative cell
source can yet replace the functionality and efficacy of primary
human hepatocytes. MSCs likely hold the greatest attribute as
immunomodulators, and co-culturing with mature donor hepa-
tocytes. More clinical trials assessing the safety and efficacy of
HLCs is pivotal before they can be considered as a reliable cell
source. In the future, this may allow for liver-based diseases to
be effectively treated without the need for OLT.
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